Our analysis of ERVK3-1 expression in clinical samples has demonstrated a potential survival detriment in patients with elevated ERVK3-1 expression, marking the first such analysis of a HERV transcript as a negative prognostic marker in GBM. The gene discussed is ERVK3-1; the disease is glioblastoma.